TIDMPRTC
PureTech Health PLC
26 May 2020
26 May 2020
PureTech Health plc
PureTech Founded Entity Vor Biopharma Appoints Nathan Jorgensen,
PhD, as Chief Financial Officer
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to discovering,
developing and commercializing highly differentiated medicines for
devastating diseases, today announced that its Founded Entity Vor
Biopharma has appointed Nathan Jorgensen, PhD, as Chief Financial
Officer.
Dr Jorgensen has over a decade of diverse experience in the
financial industry focused on healthcare and biopharma at the Qatar
Investment Authority (QIA), Calamos Investments and Stifel
Nicolaus, as well as scientific doctoral and post-doctoral
training. At QIA, the sovereign wealth fund of the State of Qatar,
Dr Jorgensen spearheaded biotechnology and pharmaceutical
investment efforts, which included opportunities in public,
private, and specialty investments. Prior to joining QIA, he led
investments in therapeutics at Calamos, a growth-focused public
equity investment firm with $25 billion of assets under management.
Before joining Calamos, Dr Jorgensen covered mid- and large-cap
biotech companies at the investment bank Stifel Nicolaus.
Prior to working on Wall Street, Dr Jorgensen investigated the
pathobiology of Parkinson's disease at the Columbia University
Medical Center as a post-doctoral scientist.
The full text of the announcement from Vor Biopharma is as
follows:
Vor Biopharma Adds to Leadership Team with Appointment of Chief
Financial Officer
CAMBRIDGE, Mass., - May 26, 2020 - Vor Biopharma , an oncology
company pioneering engineered haematopoietic stem cells (eHSCs) for
the treatment of cancer, today announced the appointment of Nathan
Jorgensen, PhD, as Chief Financial Officer. Dr Jorgensen has over a
decade of diverse experience in the financial industry focused on
healthcare and biopharma at the Qatar Investment Authority (QIA),
Calamos Investments and Stifel Nicolaus, as well as scientific
doctoral and post-doctoral training.
"Nathan is a rare combination of financial analyst and scientist
and brings these valuable skills to Vor at an important time in our
development as company," said Robert Ang, MBBS, MBA, Vor's
President and Chief Executive Officer. "In this leadership role, he
will work with us to execute on our financing strategy, allowing us
to grow our team and advance our lead programme VOR33 into the
clinic, while deepening our scientific platform and pipeline."
Dr Jorgensen brings a comprehensive background of buy-side,
sell-side, consulting, and scientific experience to his new role at
Vor. At QIA, the sovereign wealth fund of the State of Qatar, he
spearheaded biotechnology and pharmaceutical investment efforts,
which included opportunities in public, private, and specialty
investments. Prior to joining QIA, he led investments in
therapeutics at Calamos, a growth-focused public equity investment
firm with $25 billion of assets under management. Before joining
Calamos, Dr Jorgensen covered mid- and large-cap biotech companies
at the investment bank Stifel Nicolaus.
Prior to working on Wall Street, Dr Jorgensen investigated the
pathobiology of Parkinson's disease at the Columbia University
Medical Center as a post-doctoral scientist. He earned an MBA from
the Johnson School at Cornell University and a PhD from the
University of Minnesota.
"Vor's approach to engineering haematopoietic stem cells to
unlock the potential of targeted therapies is extremely compelling
and I consider it amongst the most elegant therapeutic strategies
in the field of oncology, " said Dr Jorgensen. "I look forward to
working with the team to explore potential financing opportunities
to advance our science and bring our lead therapy closer to helping
patients with blood cancers."
About Vor Biopharma
Vor Biopharma aims to transform the lives of cancer patients by
pioneering engineered haematopoietic stem cell (eHSC) therapies. By
removing biologically redundant proteins from eHSCs, these cells
become inherently invulnerable to complementary targeted therapies
while tumour cells are left susceptible, thereby unleashing the
potential of targeted therapies to benefit cancer patients in
need.
Vor's platform could be used to potentially change the treatment
paradigm of both haematopoietic stem cell transplants and targeted
therapies, such as antibody drug conjugates, bispecific antibodies
and CAR-T cell treatments. A proof-of-concept study for Vor's lead
programme has been published in Proceedings of the National Academy
of Sciences .
Vor is based in Cambridge, Mass. and has a broad intellectual
property base, including in-licenses from Columbia University,
where foundational work was conducted by inventor and Vor
Scientific Board Chair Siddhartha Mukherjee, MD, DPhil. Vor was
founded by Dr Mukherjee and PureTech Health and is supported by
leading investors including 5AM Ventures and RA Capital Management,
Johnson & Johnson Innovation - JJDC, Inc. (JJDC), Novartis
Institutes for BioMedical Research and Osage University
Partners.
About VOR33
Vor's lead product candidate, VOR33, consists of engineered
haematopoietic stem cells (eHSCs) that lack the protein CD33. Once
these cells are transplanted into a cancer patient, CD33 becomes a
far more cancer-specific target, potentially avoiding toxicity to
the normal blood and bone marrow associated with CD33-targeted
therapies. In so doing, Vor aims to improve the therapeutic window
and effectiveness of CD33-targeted therapies, thereby potentially
broadening the clinical benefit to patients suffering from AML.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 23 product candidates and one product that has been
cleared by the US Food and Drug Administration (FDA). All of the
underlying programs and platforms that resulted in this pipeline of
product candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points based
on the Company's unique insights into the biology of the brain,
immune and gut, or BIG, systems and the interface between those
systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Stephanie Simon
+1 617 651 3156 +44 (0) 20 3727 1000 +1 617 581 9333
amt@puretechhealth.com ben.atwell@FTIconsulting.com stephanie@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKKPBNNBKBCPB
(END) Dow Jones Newswires
May 26, 2020 08:05 ET (12:05 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024